1.Lam C, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 Jul;103(7):1218-1228.
2.Figueroa-Romero C, et al. Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis. Front Immunol. 2022 Feb 7;13:773288.
3.Kudlacz E, et al, Eur J harmacol, 2008, 582(1-2), 154-161.
4.Yoshida H, et al, Biochem Biophys Res Commun, 2012, 418(2), 234-240.
5.Borie DC, et al, Transplantation, 2005, 80(12), 1756-1764.
6.Calama E, et al. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther. 2017 Apr;43:60-67.